摩根士丹利发表研究报告,对内地医药股最新评级及目标价表列如下:股份|投资评级|目标价(港元)相关内容《业绩》白云山(00874.HK)首季纯利19.58亿元人民币升2.6%创新药/生物科技类首选翰森制药(03692.HK) +0.420 (+2.500%) 沽空 $1.09千万; 比率 11.506% |增持|50元信达生物(01801.HK) +0.600 (+1.556%) 沽空 $5.34千万; 比率 18.631% |增持|64─>104元药明生物(02269.HK) +0.740 (+5.808%) 沽空 $4.75千万; 比率 6.442% |增持|91.5─>130元---------------------------三生制药(01530.HK) +0.030 (+0.496%) 沽空 $1.15千万; 比率 18.746% |增持|12元康方生物-B(09926.HK) +0.250 (+0.516%) 沽空 $1.23千万; 比率 7.160% |增持|43.5元康宁杰瑞制药-B(09966.HK) +0.220 (+4.944%) 沽空 $82.20万; 比率 8.044% |增持|20元歌礼制药-B(01672.HK) -0.020 (-1.471%) |与大市同步|3元康希诺生物-B(06185.HK) +0.460 (+2.505%) 沽空 $20.15万; 比率 0.716% |增持|210─>242元石药集团(01093.HK) +0.080 (+1.227%) 沽空 $2.45千万; 比率 7.921% |增持|12.8─>11.6元基石药业-B(02616.HK) 0.000 (0.000%) |增持|14元诺诚健华-B(09969.HK) +0.060 (+1.367%) 沽空 $73.31万; 比率 5.923% |增持|17.5元李氏大药厂(00950.HK) -0.010 (-0.917%) |增持|8元欧康维视生物(01477.HK) +0.470 (+7.833%) 沽空 $42.11万; 比率 4.466% |增持|36元荣昌生物-B(09995.HK) +0.250 (+0.826%) 沽空 $3.06百万; 比率 8.567% |增持|83元中生制药(01177.HK) +0.030 (+1.095%) 沽空 $1.65千万; 比率 15.061% |增持|9.87─>10元研发及服务药明康德(02359.HK) +1.450 (+4.296%) 沽空 $1.14千万; 比率 3.587% |增持|155元互联网医药阿里健康(00241.HK) +0.200 (+7.273%) 沽空 $3.61千万; 比率 16.983% |增持|26元平安好医生(01833.HK) +0.560 (+5.344%) 沽空 $1.96千万; 比率 16.132% |增持|124─>108元相关内容《大行》大摩升中国中药(00570.HK)目标价至5.4元 评级「增持」医疗设备微创医疗(00853.HK) +0.200 (+3.509%) 沽空 $9.59百万; 比率 13.678% |增持|20.5元沛嘉医疗-B(09996.HK) 0.000 (0.000%) |增持|33.6元威高股份(01066.HK) +0.050 (+0.990%) 沽空 $1.96百万; 比率 4.770% |与大市同步|17元药厂康哲药业(00867.HK) +0.130 (+1.839%) 沽空 $1.06千万; 比率 22.962% |增持|12.5元复星医药(02196.HK) +0.260 (+2.167%) 沽空 $2.98百万; 比率 6.440% |增持|41.8元东阳光药(01558.HK) +0.300 (+2.400%) 沽空 $46.94万; 比率 1.860% |增持|15.1元丽珠医药(01513.HK) -0.100 (-0.380%) 沽空 $2.67百万; 比率 19.337% |与大市同步|34.6元绿叶制药(02186.HK) +0.020 (+0.741%) 沽空 $3.07百万; 比率 4.510% |与大市同步|3.8元先声药业(02096.HK) +0.060 (+1.145%) 沽空 $2.27百万; 比率 6.801% |增持|13元石四药集团(02005.HK) +0.050 (+1.055%) 沽空 $1.98百万; 比率 14.789% |增持|6.6元联邦制药(03933.HK) -0.290 (-2.968%) 沽空 $3.61百万; 比率 6.277% |与大市同步|7.9元医药分销商华润医药(03320.HK) +0.080 (+1.613%) 沽空 $2.14百万; 比率 4.265% |与大市同步|4.8元上海医药(02607.HK) +0.100 (+0.891%) 沽空 $2.60百万; 比率 8.559% |增持|17.8元国药控股(01099.HK) -0.200 (-0.920%) 沽空 $6.28千万; 比率 36.335% |增持|28.1元相关内容国药(01099.HK)附属国药一致首季净利润3.89亿人民币 增长7.3%医院股华润医疗(01515.HK) +0.140 (+3.509%) 沽空 $1.53百万; 比率 13.636% |增持|6.6元锦欣生殖(01951.HK) +0.140 (+5.691%) 沽空 $7.74百万; 比率 11.369% |增持|12─>14.6元原料药股海普瑞(09989.HK) +0.100 (+3.257%) |增持|18.3元传统中药股同仁堂国药(03613.HK) +0.320 (+3.448%) 沽空 $1.13百万; 比率 7.423% |增持|11.9元中国中药(00570.HK) -0.020 (-0.463%) 沽空 $1.90百万; 比率 1.015% |增持|4.7元白云山(00874.HK) +0.050 (+0.239%) 沽空 $2.55百万; 比率 12.257% |与大市同步|21元神威药业(02877.HK) +0.250 (+2.674%) 沽空 $1.03百万; 比率 13.021% |与大市同步|6.7元同仁堂科技(01666.HK) +0.380 (+7.708%) 沽空 $41.26万; 比率 2.553% |与大市同步|6.3元相关内容石药集团(01093.HK)附属石药创新首季利润7,906万人民币 倒退38.9%(da/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-26 16:25。)